心肌细胞SORBS2表达在心力衰竭中增加,并调节整合素相互作用和细胞外矩阵组成
Louk T Timmer1, Elvira den Hertog1, Danielle Versteeg1,2
1Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands.
Cardiovascular research
|February 17, 2025
概括
我们确定SORBS2是心力衰竭的关键基因,在压力心肌细胞中升高调节. 它通过GATA4的调节和整合素相互作用中的作用有助于心脏纤维化进展.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 心肌细胞压力是心力衰竭的标志.
- 了解心脏重塑的遗传基础对于开发向疗法至关重要.
研究的目的:
- 使用集成的转录基因数据识别与压力心肌细胞相关的基因.
- 研究保存基因在心脏病理学中的作用.
主要方法:
- 结合了来自人类和老鼠失败的心脏的单细胞转录基因数据集.
- 生物信息分析用于识别保存的基因.
- 利用小鼠模型和人类心脏组织进行验证.
- 亲和性净化质谱测量以确定蛋白质相互作用.
主要成果:
- 确定了SORBS2作为一个保存的NPPA相关基因.
- 在病理性心脏重塑过程中,SORBS2的表达会增加,并且与疾病的严重程度相关.
- GATA4 调节 SORBS2 的表达.
- SORBS2与整合素-细胞骨复合体相互作用.
- 在小鼠中,Sorbs2的损失通过改变整合素相互作用和细胞外矩阵组件来加剧纤维化.
结论:
- 在心力衰竭中,SORBS2以GATA4依赖的方式上调.
- SORBS2 是整合素相互作用和心脏纤维化的关键调节者.
- 准SORBS2可能为心力衰竭提供治疗潜力.
相关概念视频
Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371


